Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
about
Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome ItGSK-3 as potential target for therapeutic intervention in cancerThe insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies.Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.Effects of prolonged exposure to low dose metformin in thyroid cancer cell lines.Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma.Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion currentThe effect of metformin on breast cancer outcomes in patients with type 2 diabetesRole of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage DifferentiationMetformin: multi-faceted protection against cancer.Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary TumorigenesisIntrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implicationsAntiproliferative and apoptotic effects of a specific anti-insulin-like growth factor I receptor single chain antibody on breast cancer cells.Dissecting the Mechanisms Underlying Unusually Successful Human Health Span and Life Span.Metformin and its clinical use: new insights for an old drug in clinical practice.Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).Peroxisome proliferator-activated receptor γ coactivator 1β (PGC-1β) protein attenuates vascular lesion formation by inhibition of chromatin loading of minichromosome maintenance complex in smooth muscle cellsTristetraprolin mediates the anti-proliferative effects of metformin in breast cancer cellsMutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes.Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions.A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal.Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling.The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer.Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK.Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice.Cellular glycosylation affects Herceptin binding and sensitivity of breast cancer cells to doxorubicin and growth factors.ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapyThe promise of anti-ErbB3 monoclonals as new cancer therapeuticsTherapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic.HER2-positive breast cancer is lost in translation: time for patient-centered research.Translating the Science of Aging into Therapeutic Interventions.Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.Combinational strategies of metformin and chemotherapy in cancers.Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.Metformin as a Tool to Target Aging.
P2860
Q26752780-9F28FCC5-DCA8-40EE-A8B1-4714D18E0DBDQ27013811-61753431-12AC-42A1-BBF9-E324AF60CF0AQ30244095-B6DBE2C4-1BD1-496E-9AF8-0D7983E5776AQ30857631-401580F6-79BE-4408-9B82-FB39EDC182FFQ33702357-7DAAD57D-D059-4368-8340-143D99ADFEF0Q34051933-94B7311B-FCAA-4322-8909-019334FB9910Q34103963-43D78C61-7675-4D6F-ACC3-C9C64A81537BQ34704781-171867E3-DF91-42BD-9C9A-F85EC98A8ABFQ34957274-E321B699-6E55-47C5-819D-FE5C5245EEBBQ35000522-0CDC0E79-F71A-424E-AAB8-0A48CCC818E2Q35535296-25E2334C-B534-4170-8053-391C7E306291Q35764409-18E92550-624B-4817-863F-59DCAC115215Q35835794-D720314D-8BC8-464F-953E-057AC27585A9Q36078840-AB0287AF-4C83-41B3-A495-09160CFC67A9Q36088788-A27D474D-6366-44A3-8C15-DF910161F869Q36136323-79350526-716A-4FAA-9211-EFC1BF2C0628Q36406255-674E0B4D-418D-4043-82AD-010958F0F540Q36423076-08034286-5D73-4C0F-AA87-EE105F5A57B9Q36426509-3F11BAA4-B9C3-41BA-9129-85E76A5B6A25Q36620705-1456D680-0C1D-4EFA-B617-DCE394BB6B9CQ36678490-7797EBB2-ABCF-4F14-A66D-EB327CB9A9FCQ36862768-DFC84242-059B-4D9B-98E4-2C8FE8094348Q36926098-794773E6-85C9-4C93-AD53-02C5C928100CQ36926148-48111D7D-573B-4EC6-82E1-0E105A9A8ADCQ37029389-86677367-99E7-4178-842B-5665050A5CF6Q37087351-F2D9544D-9F5D-4FDE-BF0D-600CEB993634Q37312071-7FCAEE79-A9F0-4B9F-B7DF-A85C7C98BB6CQ37437269-ED101B06-25F7-455F-9C2B-E932C3518325Q37543714-02F6AB4E-67CA-46C0-B176-0ADD4A0D4EC3Q37640678-70FB54ED-76EB-4D36-A2CF-B907C2DD8303Q37657607-0CE3F7C3-4BC2-4436-9202-C409D7778943Q37662351-114BC0EE-CA04-43C9-BF46-869F57ED647BQ38034347-C6321C5D-15FD-4B63-AB8B-8C869F66F8DFQ38214802-0458B265-8943-470E-85C5-B8B2BA87AD31Q38648765-E67EB4AE-B44F-4E87-9BD6-BD32B19FE55AQ38756902-5E4DB93D-CA61-43A6-BAB4-DEDBAE4680CCQ38790790-FE64BFC9-42AA-4520-A655-D9CE80AAC14DQ38818730-72D0B549-5C52-468E-95DD-A73FB8E90E62Q38824661-0DC803A4-B5E9-4DF9-B041-4148D91AC85EQ38865781-7938F667-5085-474D-A18D-9005AD269896
P2860
Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Potent anti-proliferative effe ...... 2/IGF-1 receptor interactions.
@en
Potent anti-proliferative effe ...... 2/IGF-1 receptor interactions.
@nl
type
label
Potent anti-proliferative effe ...... 2/IGF-1 receptor interactions.
@en
Potent anti-proliferative effe ...... 2/IGF-1 receptor interactions.
@nl
prefLabel
Potent anti-proliferative effe ...... 2/IGF-1 receptor interactions.
@en
Potent anti-proliferative effe ...... 2/IGF-1 receptor interactions.
@nl
P2093
P356
P1433
P1476
Potent anti-proliferative effe ...... B2/IGF-1 receptor interactions
@en
P2093
Ann D Thor
Stuart E Lind
Susan M Edgerton
XiaoHe Yang
Zeying Fan
P304
P356
10.4161/CC.10.17.16359
P50
P577
2011-09-01T00:00:00Z